Vmbook Online ordering

Mastercard Incorporated

The company you're referring to is likely Mallinckrodt PLC (NYSE: MNK), which is a publicly-traded company that provides clinical solutions and pharmaceutical therapies, including specialty generics and imaging agents.

In terms of financial performance, here are some key figures:

* Revenue: Mallinckrodt's revenue for the most recent quarter (Q3 2021) was $612.8 million, representing a year-over-year increase of 4.4%.

* Net Income: The company's net income for Q3 2021 was $30.1 million, compared to a net loss of $122.2 million in the same period last year.

* Earnings Per Share (EPS): Mallinckrodt's EPS for Q3 2021 was $0.15, up from a loss per share of $0.69 in Q3 2020.

As for growth, here are some relevant figures:

* Annual Revenue Growth Rate (5-Year CAGR): Mallinckrodt's revenue has grown at a compound annual growth rate (CAGR) of -2.6% over the past five years.

* Annual Net Income Growth Rate (5-Year CAGR): The company's net income has declined at a CAGR of -40.3% over the past five years.

* Annual EPS Growth Rate (5-Year CAGR): Mallinckrodt's EPS has decreased at a CAGR of -42.3% over the past five years.

It's important to note that Mallinckrodt has faced significant legal and financial challenges in recent years, including investigations and lawsuits related to its opioid painkiller marketing practices, as well as debt obligations and restructuring efforts. As a result, the company's financial performance and growth prospects may be subject to significant risks and uncertainties. As always, it's recommended to conduct thorough research and seek the advice of a financial advisor before making investment decisions.